Trump FDA overhauls COVID-19 vaccine approval
Digest more
No, this is not true. Vaccines undergo rigorous safety testing and are continuously monitored for adverse events.
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by Novavax,
The most commonly reported adverse events with the AZD1222 COVID-19 vaccine are headache and fatigue, a large-scale active surveillance study from the United Kingdom shows.
Under a new policy announced Tuesday by the Trump administration, only people age 65 and older and children or young adults with certain health conditions that puts them at risk will be approved for the shot.
In recent interviews, Health and Human Services Secretary Robert F. Kennedy Jr. has minimized the risk COVID-19 poses to kids and exaggerated the risk of the vaccine, incorrectly claiming that the shot poses a “profound risk” to children.
Since the COVID-19 pandemic, there has been a decline in U.S. vaccine uptake, while widespread misinformation and distrust make it challenging to craft effective public health responses.
Live Science on MSN1d
2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayedLate-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.
Feedback